Professor David Jackson: key facts
- Kind of voice
- Clinician
- Role
- Respiratory Medicine expert at King's College London, and Clinical Lead of the asthma services across Guy's and Royal Brompton Hospitals, Guy's and St Thomas' NHS Foundation Trust
- Quoted on
- Respiratory (asthma/COPD)
- Tracked press citations
- 3
- Most recently quoted
- 30 Sept 2026
- First quoted
- 10 Sept 2026
“The WAYFINDER study is an important step forward for patients with the most severe form of asthma who require daily oral steroids in order to achieve reasonable disease control. In this International, multicentre clinical trial of more than 300 patients, the NICE-approved asthma treatment tezepelumab, a biologic therapy that targets asthma-related inflammation but without all the side effects of steroids, was capable of allowing the vast majority of patients to wean their steroids down to a low dose with over half able to stop their steroids altogether.”
What Professor David Jackson has said
“As tezepelumab also suppresses allergy-related symptoms and improves chronic rhinosinusitis as well, the results are particularly exciting for patients with severe asthma who suffer with both upper and lower airway symptoms.”
respiratory medicine expert at King's College London and asthma services clinical lead at Guy's and Royal Brompton hospitals · Respiratory (asthma/COPD) · 10 Sept 2026 · Severe asthma can be controlled by a monthly injection, trial finds ↗
“In this International, multicentre clinical trial of more than 300 patients, the NICE-approved asthma treatment tezepelumab, a biologic therapy that targets asthma-related inflammation but without all the side effects of steroids, was capable of allowing the vast majority of patients to wean their steroids down to a low dose with over half able to stop their steroids altogether.”
clinical lead of the asthma services at Guy's and St Thomas' NHS Foundation Trust and professor of respiratory immunology at King's College London · Respiratory (asthma/COPD) · 10 Sept 2026 · Half of severe asthma patients started on tezepelumab able to stop oral steroids ↗
Where Professor David Jackson has been quoted
- Monthly injection helps severe asthma patients safely stop or reduce daily steroidskcl.ac.uk · 30 Sept 2026
- Severe asthma can be controlled by a monthly injection, trial findstheguardian.com · 10 Sept 2026
- Half of severe asthma patients started on tezepelumab able to stop oral steroidspulsetoday.co.uk · 10 Sept 2026
Related media coverage
Recent UK press coverage of their topics — not necessarily citing them directly.
Doctors, nurses, allied health professionals and other registered clinicians quoted in a clinical capacity. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.